It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
The federal court has ruled that a company may patent genetic material that has been extracted from the human body, in a move that may have serious repercussions for the future of medical research in Australia.
Cancer Voices Australia began legal action over patents associated with a gene known as BRCA1 in 2010. Mutated versions of this gene, which women can be born with, have been associated with an increased risk of hereditary breast and ovarian cancers.
“[The patenting of this material] places limits on genetic testing, genetic research and the development of treatments and cures for genetically associated disease,” the Maurice Blackburn lawyer Rebecca Gilsenan said.
There is a petition you can sign that tells Myriad Genetics to stop trying to profit off breast cancer victims.
Myriad Genetics wants to make big money and this is one of their many plans on the go.
originally posted by: Sabiduria
a reply to: Unity_99
That may be the case but it still got approval anyway. Myriad Genetics wants to make big money and this is one of their many plans on the go.
The thing is, the judge agreed that Australian law allows the patent. Australian law differs from US law. That's why the decision is contrary to what the US supreme court has ruled.
You mean they should not be able to recoup their research costs through licensing the gene and the method used to isolate it? That doesn't leave a lot of incentive for private research, does it?
Yes advanced research requires money but that doesn't mean that a company should hold a monopoly on a cancer gene.
I don't know how else to phrase it for you, me no likey privatized cancer research. Should be available for all.